Form 8-K - Current report:
SEC Accession No. 0001708599-25-000013
Filing Date
2025-02-03
Accepted
2025-02-03 16:05:03
Documents
15
Period of Report
2025-02-03
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ser-20250203.htm   iXBRL 8-K 24923
2 EX-99.1 ser-20250203xex991juvfinan.htm EX-99.1 12858
6 serina.jpg GRAPHIC 25652
  Complete submission text file 0001708599-25-000013.txt   288377

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ser-20250203.xsd EX-101.SCH 1800
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ser-20250203_lab.xml EX-101.LAB 54435
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ser-20250203_pre.xml EX-101.PRE 31811
17 EXTRACTED XBRL INSTANCE DOCUMENT ser-20250203_htm.xml XML 3013
Mailing Address 601 GENOME WAY SUITE 2001 HUNTSVILLE AL 35806
Business Address 601 GENOME WAY SUITE 2001 HUNTSVILLE AL 35806 (256) 327-9630
Serina Therapeutics, Inc. (Filer) CIK: 0001708599 (see all company filings)

EIN.: 821436829 | State of Incorp.: AL | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38519 | Film No.: 25582478
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)